Loading...
XNAS
ABEO
Market cap243mUSD
Dec 04, Last price  
4.87USD
1D
2.96%
1Q
-29.32%
Jan 2017
-95.98%
Name

Abeona Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ABEO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
82.74%
Rev. gr., 5y
3.14%
Revenues
0k
-100.00%
0057,000291,000352,000481,0001,848,0004,404,0002,042,000925,0001,040,000889,000837,0002,998,000010,000,0003,000,0001,414,0003,500,0000
Net income
-64m
L+17.62%
-1,700,000-12,874,000-21,856,000-17,215,000-17,340,000-7,537,000-2,532,000-10,532,0004,449,000-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,682,000-88,349,000-88,606,000-31,809,000-54,188,000-63,734,000
CFO
-56m
L+51.36%
-7,301,000-1,958,0004,843,000-6,560,000-2,248,000-6,860,000-7,609,000-3,955,0001,000-1,611,000-10,423,000-13,014,000-22,935,000-39,111,000-62,820,000-35,019,000-65,665,000-43,483,000-37,009,000-56,015,000
Dividend
Mar 31, 20000.593 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
URL
https://abeonatherapeutics.com/
IPO date
Sep 19, 1980
Employees
57
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT